alexa Preeradication vaccine policy options for poliovirus infection and disease control.
Immunology

Immunology

Journal of Vaccines & Vaccination

Author(s): Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH,

Abstract Share this page

Abstract With the circulation of wild poliovirus (WPV) types 1 and 3 continuing more than a decade after the original goal of eradicating all three types of WPVs by 2000, policymakers consider many immunization options as they strive to stop transmission in the remaining endemic and outbreak areas and prevent reintroductions of live polioviruses into nonendemic areas. While polio vaccination choices may appear simple, our analysis of current options shows remarkable complexity. We offer important context for current and future polio vaccine decisions and policy analyses by developing decision trees that clearly identify potential options currently used by countries as they evaluate national polio vaccine choices. Based on a comprehensive review of the literature we (1) identify the current vaccination options that national health leaders consider for polio vaccination, (2) characterize current practices and factors that appear to influence national and international choices, and (3) assess the evidence of vaccine effectiveness considering sources of variability between countries and uncertainties associated with limitations of the data. With low numbers of cases occurring globally, the management of polio risks might seem like a relatively low priority, but stopping live poliovirus circulation requires making proactive and intentional choices to manage population immunity in the remaining endemic areas and to prevent reestablishment in nonendemic areas. Our analysis shows remarkable variability in the current national polio vaccine product choices and schedules, with combination vaccine options containing inactivated poliovirus vaccine and different formulations of oral poliovirus vaccine making choices increasingly difficult for national health leaders. © 2013 Society for Risk Analysis. This article was published in Risk Anal and referenced in Journal of Vaccines & Vaccination

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ivana Stojanovic
    New protocol for the generation of insulin-specific T regulatory cells
    PPT Version | PDF Version
  • Jessy S Deshane
    Longitudinal changes in airway microbiome signatures and immunoregulatory cell dynamics following Bronchial Thermoplasty
    PPT Version | PDF Version
  • Bozena Futoma-Koloch
    C3 component deposition on Salmonella O48 cells characterized by sialylated lipopolysaccharide and different pattern of outer membrane proteins
    PPT Version | PDF Version
  • Luis Gosalbez
    Key regulatory issues in the development of pharmabiotics in Europe
    PPT Version | PDF Version
  • Brian Littlechild
    The management of violence and aggression against staff in mental health work: responding effectively through a co-production approach to issues for service users, carers, staff and agencies
    PPT Version | PDF Version
  • Raja Roy
    Disruption in the US machine tool industry: The role of in house users and pre-disruption component experience in fi rm response
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Kazuo Yano
    Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
    PPT Version | PDF Version
  • Pierre Moine
    Systemic Antimicrobial Prophylaxis Issues
    PPT Version | PDF Version
  • Jan O Gordeladze
    Key regulatory junctions stabilizing the osteoblast phenotype: Implications for cell and tissue engineering
    PPT Version | PDF Version
  • Jane E Clougherty
    Issues of air pollution exposure science and epidemiology
    PPT Version | PDF Version
  • M Sudharani
    Genetic analysis of components of salinity tolerance in Rice (Oryza sativa L.)
    PPT Version | PDF Version
  • L C De
    Orchid- A diversified component of farming systems for profitability and livelihood security
    PPT Version | PDF Version
  • Dean A
    Identifying physical and psycho-social issues facing breast cancer survivors after definitive treatment for early breast cancer: a nurse-led clinic model
    PPT Version | PDF Version
  • Shulamith Kreitler
    Where, when and how to die: Insights into issues of critical nursing in cancer
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords